Table 5.

Session product characteristics’ effects on symptom relief when using inhaled, dried Cannabis flower and treating cannabinoid measurements as categorical variables

	Overall sample	Agitation/irritability	Anxiety	Stress
	(1)	(2)	(3)	(4)
THC 10–19%/dry wt.	− 0.377** (0.123)	− 0.472 (0.469)	− 0.618*** (0.170)	− 0.024 (0.167)
THC 20–30%/dry wt.	− 0.345** (0.117)	− 0.131 (0.452)	− 0.599*** (0.165)	0.214 (0.162)
CBD 1–9%/dry wt.	0.007 (0.138)	− 0.333 (0.217)	0.120 (0.152)	0.518 (0.411)
CBD 10–30%/dry wt.	− 0.057 (0.188)	− 0.270 (0.292)	− 0.051 (0.199)	0.530 (0.409)
C. indica	− 0.024 (0.106)	− 0.163 (0.200)	0.037 (0.141)	− 0.110 (0.174)
C. sativa	0.212* (0.104)	0.068 (0.243)	0.231 (0.131)	− 0.227 (0.171)
Pipe	0.079 (0.260)	0.418 (0.646)	− 0.41 (0.220)	0.116 (0.265)
Vape	0.146 (0.274)	0.634 (0.672)	− 0.229 (0.257)	0.089 (0.313)
Session length (min)	− 0.007*** (0.001)	− 0.005* (0.002)	− 0.007*** (0.001)	− 0.008*** (0.001)
Baseline symptom intensity	− 0.661*** (0.039)	− 0.693*** (0.072)	− 0.604*** (0.067)	− 0.667*** (0.052)
Constant	0.219 (0.300)	− 0.105 (0.848)	0.649 (0.350)	− 0.402 (0.478)
Number of sessions	2306	422	998	886
Number of users	670	206	441	360

Each column represents a separate regression. The outcome is the difference between the lowest reported symptom level within 4 h of initiating the session and the starting symptom level. The first column reports results for the whole sample, while columns 2 to 4 distinguish between specific distress-related symptoms reported. The omitted category for the THC categories is THC less than 10% and for the CBD categories is CBD equal to 0%. C. indica and C. sativa are relative to hybrid strains, and pipe and vape are relative to joint. All regressions are estimated using a fixed effects model and control for session length and baseline symptom intensity. Standard errors, clustered at the individual user level, are shown in parentheses

***p < 0.001, **p < 0.01, *p < 0.05